Xoma | XOMA

Xoma traded at $20.84 this Friday July 1st, decreasing $1.44 or 6.46 percent since the previous trading session. Looking back, over the last four weeks, Xoma lost 16.42 percent. Over the last 12 months, its price fell by 37.42 percent. Looking ahead, we forecast Xoma to be priced at 20.24 by the end of this quarter and at 18.65 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
20.84
Daily Change
-6.46%
Yearly
-37.42%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
AbbVie 153.80 0.64 0.42% 33.54%
Agenus 1.96 0.02 1.03% -64.49%
Agios Pharmaceuticals 23.36 1.19 5.37% -58.08%
Ardelyx 0.59 0.004 0.70% -92.47%
Bluebird Bio 4.28 0.14 3.38% -86.36%
BioMarin Pharmaceutical 84.98 2.11 2.55% -0.57%
Celldex Therapeutics 22.70 -4.26 -15.80% -32.94%
Chimerix 2.14 0.06 2.88% -74.31%
Curis 0.94 -0.04 -4.50% -87.74%
Emergent BioSolutions 31.83 0.79 2.55% -50.08%
Epizyme 1.48 0.01 0.68% -81.41%
Intercept Pharmaceuticals 14.13 0.32 2.32% -29.31%
Incyte Corp 77.67 1.70 2.24% -7.07%
Life Technologies 2.85 0.02 0.71% -41.12%
Eli Lilly 324.71 0.48 0.15% 38.79%
MacroGenics 3.05 0.10 3.39% -89.37%
Novartis 80.33 -0.52 -0.64% -4.96%
Novartis 84.36 -0.17 -0.20% -8.28%
Pfizer 52.31 -0.12 -0.23% 31.66%
Prothena 27.89 0.74 2.73% -49.72%
Regeneron Pharmaceuticals 595.40 4.27 0.72% 2.01%
Teva Pharmaceutical Industries 7.89 0.37 4.92% -19.74%
Xoma 20.84 -1.44 -6.46% -37.42%

Indexes Price Day Year
USND 11128 99.11 0.90% -23.99%
US2000 1728 19.77 1.16% -25.07%

Xoma
XOMA Corporation (XOMA) is a biotechnology royalty aggregator. The Company's drug royalty aggregator business is focused on early to mid-stage clinical assets primarily in Phase I and II. XOMA acquires pre-commercial therapeutic candidates that is licensed to pharmaceutical or biotechnology companies. Its product candidates include PTH1R, a G-protein-coupled receptor involved in the regulation of calcium metabolism; XMetA, an insulin receptor-activating antibody, and X213, an allosteric inhibitor of prolactin action. It has a range of antibody discovery and development technologies, which includes antibody discovery advanced platform technologies (ADAPT), ModulX and OptimX. The ADAPT technology includes phage display libraries integrated with yeast and mammalian display. Its ModulX technology enables the identification of allosteric antibodies for positive or negative modulation of biological pathways. The OptimX technology is used for optimizing biophysical properties of antibodies.